Glecaprevir
Produktgrößen
1 mg
£199,00
15-4007-1MG
5 mg
£419,00
15-4007-5MG
Über dieses Produkt
- SKU:
- 15-4007
- Zusätzliche Namen:
- A-1282576; ABT-493
- Weitere Details:
- Molecular Formula: C38H46F4N6O9S Molecular Weight: 838.9 Glecaprevir is an orally bioavailable and direct-acting inhibitor of the hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease.It inhibits NS3/4A from HCV genotypes 1a; 1b; 2a; 2b; 3a; 4a; 5a; and 6a (IC50s = 4.6; 8.9; 3.5; 3.8; 7.9; 6.1; 8.1; and 11.3 nM; respectively) in cell-free assays but does not inhibit human chymase; chymotrypsin type II; chymotrypsin type VII; elastase; kallikrein; urokinase; or cathepsin B proteases (IC50s = >200;000 nM). Glecaprevir inhibits HCV replication in stable Huh7-derived replicon cells infected with subgenomic genotypes 1a; 1b; 2a; 2b; 3a; 4a; 5a; and 6a (EC50s = 0.85; 0.94; 2.2; 4.6; 1.9; 2.8; 1.4; and 0.86 nM; respectively). It also inhibits replication of clinical isolates of genotypes 1a (EC50s = 0.05-0.12 nM); 1b (EC50s = 0.20-0.68 nM); 2a (EC50s = 0.66-1.9 nM); 2b (EC50s = 1.4-3.2 nM); 3a (EC50s =0.71-3.8 nM); and 4a (EC50s = 0.31-0.55 nM). Glecaprevir acts synergistically with the HCV NS5A protease inhibitor pibrentasvir (Item No. 27546) to inhibit HCV genotype 1b-Con1 replication in replicon cells. Formulations containing glecaprevir; in combination with pibrentasvir; have been used in the treatment of chronic HCV genotype 1; 2; 3; 4; 5; or 6 infection.
- Aufreinigung:
- >=98%
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- Store at -20[o]C; product is stable for at least two years.
- Hersteller:
- Abeomics
- Typ:
- Biomaterials
- Datenblatt des Herstellers:1.png